Generic Zunveyl Availability
Last updated on Apr 10, 2025.
Zunveyl is a brand name of benzgalantamine, approved by the FDA in the following formulation(s):
ZUNVEYL (benzgalantamine gluconate - tablet, delayed release;oral)
-
Manufacturer: ALPHA COGNITION
Approval date: July 26, 2024
Strength(s): EQ 5MG BASE [RLD], EQ 10MG BASE [RLD], EQ 15MG BASE [RLD]
Is there a generic version of Zunveyl available?
No. There is currently no therapeutically equivalent version of Zunveyl available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zunveyl. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Solid forms of Alpha-1062 gluconate
Patent 11,795,176
Issued: October 24, 2023
Inventor(s): Sancilio; Fred D.
Assignee(s): Alpha Cognition Inc. (Vancouver, CA)The invention relates to crystalline forms of Alpha-1062 gluconate. In one aspect, the invention relates to a crystalline solid form of Alpha-1062 gluconate (Form A), wherein said crystalline form has prominent peaks at 3.61, 10.98, 14.41 and 18.44 degrees 2-theta (±0.2) in a powder X-ray diffraction pattern. The invention further relates to methods for manufacturing crystalline forms and compositions comprising said crystalline forms.
Patent expiration dates:
- January 13, 2042✓✓
- January 13, 2042
-
Process for making dry and stable hemostatic compositions
Patent 12,208,176
Issued: January 28, 2025
Inventor(s): Goessl; Andreas et al.
Assignee(s): Baxter International Inc. (Deerfield, IL); Baxter Healthcare SA (Glattpark, CH)Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent, b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis, c) providing said first component and said second component in a combined form in a final container, c1) either by filling said first component and said second component into said final container so as to obtain a dry mixture in said final container, c2) or by providing said first component or said second component in said final container and adding said second component or said first component so as to obtain a combination of said first component with said second component in said final container, d) finishing the final container to a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.
Patent expiration dates:
- February 26, 2044✓✓
- February 26, 2044
-
Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
Patent 9,763,953
Issued: September 19, 2017
Inventor(s): Maelicke Alfred
Assignee(s): NEURODYN LIFE SCIENCES INC.The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline, and their exogenous agonists, of neuronal cholinergic receptors and/or acting as cholinesterase inhibitors and/or neuroprotective agents, have enhanced blood-brain barrier permeability in comparison to their parent compounds. The compounds are derived (either formally by their chemical structure or directly by chemical synthesis) from natural compounds belonging to the class of amaryllidaceae alkaloids e.g., galantamine, narwedine and lycoramine, or from metabolites of said compounds. The compounds of the present invention can either interact as such with their target molecules, or they can act as “pro-drugs”, in the sense that after reaching their target regions in the body they are converted by hydrolysis or enzymatic attack to the original parent compound and react as such with their target molecules, or both. The compounds of this invention may be used as medicaments.
Patent expiration dates:
- December 1, 2026✓
- December 1, 2026
More about Zunveyl (benzgalantamine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- Dosage information
- FDA approval history
- Drug class: cholinesterase inhibitors
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.